about
Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosisOpen data in drug discovery and development: lessons from malariaDesigning the next generation of medicines for malaria control and eradicationOpen Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesA long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaThe design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritisStructure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate PotentialFluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase InhibitorsA triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malariaOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondKilling the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivaxNew developments in anti-malarial target candidate and product profilesP. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-actionThe open access malaria box: a drug discovery catalyst for neglected diseasesCharacterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy ModelingPyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.Assessing the anthelmintic activity of pyrazole-5-carboxamide derivatives against Haemonchus contortus.ProSAR: a new methodology for combinatorial library design.Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum.Novel orally active antimalarial thiazoles.Quinolone-3-diarylethers: a new class of antimalarial drug.Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in miceSubtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparumCyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen.ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria.A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments.The global pipeline of new medicines for the control and elimination of malariaTetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial ActivityIn vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models.Antimalarial drug discovery - the path towards eradication.Arylmethylamino steroids as antiparasitic agents.Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination.The state of the art in anti-malarial drug discovery and development.Challenges in antimalarial drug discovery.Defining the biology component of the drug discovery strategy for malaria eradication.Hit and lead criteria in drug discovery for infectious diseases of the developing world.
P50
Q24630917-1B914115-009D-45CE-9A97-BB1C8C63472FQ26742211-6E66D5F1-F077-4904-8BEE-C79F26A6A3DBQ26859195-F0BF1BF1-E53C-4BC5-9443-6042487CCE7BQ26883657-5375C9F8-E024-46E1-A6C3-ADB1976437A1Q27644391-8DCBEB90-01E8-44FC-B0BD-A1FE9CBF9A06Q27666686-D304965F-1844-4FB4-9C67-74D6AB6B59A7Q27670499-89E2AEC0-5AEE-4A09-8C43-7F4B92DA8610Q27683656-3EFC48A2-2F62-4ADF-86E7-C739297C25B2Q27728080-934D56D8-0411-42B0-9458-1F956497EBB2Q27826351-4943868C-750E-4E6B-9419-F36F30BC4834Q28081463-0422EE72-658B-45CE-96F4-B4F62D498CE9Q28468598-674F7F99-D19B-4635-8300-C0DCF93C2F98Q28481199-7308029C-E122-4F05-8056-7DE98C9153A7Q28533977-8478D781-365B-46D2-A4C5-DBEAFA78C291Q28554466-ACF6E5DE-AE08-406C-8735-4BD90714A6CFQ28649962-18044FA1-73D6-426D-8B74-520CA3CA7E97Q30365580-20E1E112-5A54-471A-97B3-2F4BD3B99A96Q30854256-1590CB7D-F2F7-49DA-A0C4-372A11017954Q33444133-4B827AB7-CF7A-41DB-A195-5C9889F31069Q33599811-5C51F1D4-B4C9-4B55-8271-4F22DD6C77CEQ33630572-BC41033A-4F4E-4371-B02F-F828616933D4Q33891625-2E424123-940D-45C2-BE83-93E433849480Q34038515-75DAAE2D-66B3-488A-98B7-D810141F44BAQ34334269-2E174EAD-B6D1-4911-B7A6-28F074360791Q34525226-02A07D13-17A3-403E-A75B-E031B475C516Q35071496-D68C9AF5-7E80-4D73-B1A3-066A2BA675F2Q35168943-610B5C79-B091-4609-BFDC-5BE2FCBD5AFAQ35598598-CE28E5E8-0811-47E8-BC13-6CE7B90CC3B2Q35960668-90AA3F92-AB28-435B-BE98-9FFED7FE337FQ36137064-294AF00C-B058-4B4E-875C-A7D03CCCBD1FQ36320249-88ECC45B-AACF-4540-A231-624682CCF0E7Q36996257-A6B20326-8F3A-4B03-ABAD-099B688F40D2Q37320938-149DA1AB-DB3A-4F7A-823C-720C7CE92657Q37449662-0E63FEF4-4A9B-4405-8281-E50AD36DFDA7Q37660615-0413DD66-4737-4086-97C5-B361783D1D95Q37687630-199BC504-A1CF-4DD5-B841-B6364FE39597Q37852739-7919B57A-80DB-4AF4-94AA-097C1210DA2CQ37924296-06F1A65F-1CC9-49A9-B2D6-213211F54463Q38240672-EDF31408-A242-4AFF-BCE3-8F46C5E0484FQ38599011-6521FA7E-520F-4F63-932A-FA60D1E23FAE
P50
name
Jeremy N Burrows
@en
type
label
Jeremy N Burrows
@en
prefLabel
Jeremy N Burrows
@en